Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Short sleepers are four times more likely to catch a cold

  • Men who buy sex have much in common with sexually coercive men

  • With tobacco, what you don't know can kill you sooner

  • New type of prion may cause, transmit neurodegeneration

  • Medication treatment for opioid use disorders in primary care increases patient access

  • Research in mice shows potential value of antidepressant in some stroke victims

  • Dialect influences Appalachian students' experiences in college

  • We've all got a blind spot, but it can be shrunk

  • Predictor of child vocabulary in early speech

  • Raising pay can reduce smoking rates

  •